A Multicenter, Open-label, Single-arm, Extension Study to Assess Long-term Safety of Evolocumab Therapy in Subjects With Clinically Evident Cardiovascular Disease in Selected European Countries
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 08 Jan 2019
At a glance
- Drugs Evolocumab (Primary)
- Indications Dyslipidaemias
- Focus Adverse reactions
- Sponsors Amgen
- 26 Oct 2018 Planned End Date changed from 4 Nov 2022 to 4 Dec 2022.
- 26 Oct 2018 Planned primary completion date changed from 4 Nov 2022 to 4 Dec 2022.
- 31 Aug 2018 Biomarkers information updated